Search research articles
Contact Us
Filters
Showing results (21-30 of 25) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 25 results.
Contact Dermatitis
|
October 1, 1986
Airborne contact urticaria due to cinchona
A Dooms-Goossens, H Deveylder, C Duron, et al.
Methods (San Diego, Calif.)
|
August 23, 2012
Improving biological relevancy of transcriptional biomarkers experiments by applying the MIQE guidelines to pre-clinical and clinical trials
M Dooms, A Chango, E Barbour, et al.
Contact Dermatitis
|
May 1, 1987
Zinc ricinoleate: sensitizer in deodorants
A Dooms-Goossens, K Dupré, A Borghijs, et al.
Drug Discovery Today
|
March 23, 2025
Drug-device combinations in rare diseases: Challenges and opportunities
E A Tataru, M Dooms, C Gonzaga-Jauregui, et al.
Expert Review of Medical Devices
|
September 20, 2024
Orphan and paediatric medical devices in Europe: recommendations to support their availability for on-label and off-label clinical indications
Tom Melvin, Marc M Dooms, Berthold Koletzko, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 25) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 25 results.
Contact Dermatitis
|
October 1, 1986
Airborne contact urticaria due to cinchona
A Dooms-Goossens, H Deveylder, C Duron, et al.
Methods (San Diego, Calif.)
|
August 23, 2012
Improving biological relevancy of transcriptional biomarkers experiments by applying the MIQE guidelines to pre-clinical and clinical trials
M Dooms, A Chango, E Barbour, et al.
Contact Dermatitis
|
May 1, 1987
Zinc ricinoleate: sensitizer in deodorants
A Dooms-Goossens, K Dupré, A Borghijs, et al.
Drug Discovery Today
|
March 23, 2025
Drug-device combinations in rare diseases: Challenges and opportunities
E A Tataru, M Dooms, C Gonzaga-Jauregui, et al.
Expert Review of Medical Devices
|
September 20, 2024
Orphan and paediatric medical devices in Europe: recommendations to support their availability for on-label and off-label clinical indications
Tom Melvin, Marc M Dooms, Berthold Koletzko, et al.
Page
of 3